Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Noelia Vigo-Díaz has a total of 5 co-authors. Here are the top co-authors by number of shared publications:

  • Cristina Núñez

    Inorganic Chemistry Department, Institute for Research in Global Health and Sustainable Development (iTERRA), Faculty of Sciences, Campus Terra, University of Santiago de Compostela, 27002 Lugo, Spain

    2 shared publications
  • Laura Rodríguez-Silva

    Inorganic Chemistry Department, Institute for Research in Global Health and Sustainable Development (iTERRA), Faculty of Sciences, Campus Terra, University of Santiago de Compostela, 27002 Lugo, Spain

    2 shared publications
  • Rubén López-Cortés

    Research Unit, Hospital Universitario Lucus Augusti (HULA), Servizo Galego de Saúde (SERGAS), 27002 Lugo, Spain

    2 shared publications
  • Isabel Velo-Heleno

    Departamento de Química Inorgánica, Facultade de Química, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain

    1 shared publication
  • Marcelino Maneiro

    Inorganic Chemistry Department, Institute for Research in Global Health and Sustainable Development (iTERRA), Faculty of Sciences, Campus Terra, University of Santiago de Compostela, 27002 Lugo, Spain

    1 shared publication

Latest Publications

  • Open Access

    Decoding the Collagenome in Breast Cancer: Mechanotransduction, Microenvironment, and Translational Opportunities

    by Noelia Vigo-Díaz, Rubén López-Cortés, Laura Rodríguez-Silva, Marcelino Maneiro, Cristina Núñez

    Breast cancer (BC) progression is strongly influenced by the extracellular matrix (ECM), whose remodelling regulates tumour growth, invasion, metastasis, immune modulation, and therapeutic response. Among ECM components, collagens have emerged as both structural proteins and active mediators of mechanotransduction, stromal interactions, and tumour cell behaviour. This narrative review analyses collagen families and collagen-associated proteins implicated in BC, integrating evidence on their expression patterns, biological functions, clinical significance, and translational potential. We examine fibrillar and non-fibrillar collagens, including fibril-associated collagens with interrupted triple helices (FACITs), membrane-associated collagens with interrupted triple helices (MACITs), basement membrane (BM) collagens, and multiplexins, together with their interactions with cancer-associated fibroblasts (CAFs), immune cells, and signalling pathways involved in tumour progression. Alterations in collagen composition, organization, crosslinking, and degradation regulate ECM stiffness, epithelial–mesenchymal transition (EMT), invasion, metastatic dissemination, and therapy resistance. Several collagen types and collagen-derived fragments also show promise as prognostic biomarkers and therapeutic targets, particularly in aggressive BC subtypes such as human epidermal growth factor receptor 2 (HER2)-positive and triple-negative breast cancer (TNBC). Overall, this review highlights the collagenome as a dynamic component of the breast tumour microenvironment (TME) and supports collagen-informed strategies for improved patient stratification and targeted therapies.

  • Open Access

    Proteoglycans in Breast Cancer: Friends and Foes

    by Noelia Vigo-Díaz, Rubén López-Cortés, Isabel Velo-Heleno, Laura Rodríguez-Silva, Cristina Núñez

    Proteoglycans (PGs) are highly glycosylated proteins of great importance both structurally and for signalling in the extracellular matrix (ECM) as well as cell surfaces. In breast cancer (BC), they control the structure of tissue architecture, cellular communication pathways and tumour–stroma interactions, thus affecting adhesion, migration, angiogenesis, immune evasion, and metastasis. Their structural heterogeneity supports either subtype- or context-dependent functions. This review combines current studies of PGs in BC according to their classification into intracellular, cell-surface, pericellular, extracellular, and small leucine-rich PGs and a range of non-classical PGs. A literature-driven approach to focus on molecular mechanisms and clinical correlations will demonstrate how PGs respond with collagens, growth factors, cytokines, and proteolytic enzymes in order to modulate the ECM and affect therapy resistance. Indeed, PGs including syndecans, glypicans, perlecan, versican, biglycan and decorin showed the potential to be promoters or suppressors of cancer, with local effects on invasion, and have a significant modulating effect on BC subtypes or the prognosis and therapeutic response and may potentially serve as new biomarkers for stratification and liquid biopsy candidates. Furthermore, PGs appear to modulate the tumour immune landscape, are involved in the development of metastatic niches, and underlie signalling pathways like Wnt or TGFβ in a subtype-dependent manner, extending their translational prospects and therapeutic utility. PGs, taken together, seem to be major modulators of BC, with particular relevance for precision medicine.